Moderna Historical Cash Flow
| MRNA Stock | USD 31.26 0.94 2.92% |
Analysis of Moderna cash flow over time is an excellent tool to project Moderna future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Depreciation of 151.3 M or Capital Expenditures of 1.1 B as it is a great indicator of Moderna ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Moderna latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Moderna is a good buy for the upcoming year.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. About Moderna Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Moderna balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Moderna's non-liquid assets can be easily converted into cash.
Moderna Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Dividends Paid
The total amount of dividends that a company has paid out to its shareholders over a specific period.Most accounts from Moderna's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Moderna current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.At present, Moderna's Sale Purchase Of Stock is projected to decrease significantly based on the last few years of reporting. The current year's Total Cashflows From Investing Activities is expected to grow to about 2 B, whereas Change In Cash is projected to grow to (949 M).
Moderna cash flow statement Correlations
Click cells to compare fundamentals
Moderna Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Moderna cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Sale Purchase Of Stock | (8.2M) | 2.9M | 7.0M | (857M) | (3.3B) | (1.2B) | |
| Change In Cash | 2.4B | 4.2B | (3.6B) | (289M) | (999M) | (949.1M) | |
| Net Borrowings | 971K | (6.2M) | (140M) | (184M) | (165.6M) | (157.3M) | |
| Total Cashflows From Investing Activities | (1.7B) | (8.5B) | (5.2B) | 4.2B | 1.9B | 2.0B | |
| Other Cashflows From Financing Activities | 186.7M | 124M | (5.2B) | 4.2B | 56M | 38.1M | |
| Depreciation | 31.3M | 232M | 348M | 621M | 189M | 151.3M | |
| Capital Expenditures | 67.4M | 284M | 400M | 707M | 1.1B | 1.1B | |
| Total Cash From Operating Activities | 2.0B | 13.6B | 5.0B | (3.1B) | (3.0B) | (2.9B) | |
| Change To Account Receivables | (1.4B) | (1.8B) | 1.8B | 493M | 534M | 560.7M | |
| Change To Operating Activities | 7.2M | 154.6M | 582M | (992M) | (892.8M) | (848.2M) | |
| Net Income | (747.1M) | 12.2B | 8.4B | (4.7B) | (3.6B) | (3.4B) | |
| Total Cash From Financing Activities | 2.0B | (873M) | (3.4B) | (1.4B) | 56M | 58.8M | |
| Change To Netincome | 81.4M | 155.5M | (176M) | (305M) | (274.5M) | (260.8M) | |
| Change To Liabilities | (77.6M) | 406.3M | 2.2B | 112M | 128.8M | 122.4M | |
| End Period Cash Flow | 2.6B | 6.9B | 3.2B | 2.9B | 1.9B | 2.1B | |
| Change To Inventory | (46.5M) | (1.4B) | 492M | 747M | 83M | 87.2M | |
| Investments | (1.6B) | (8.2B) | (5.2B) | 3.7B | 1.9B | 2.0B | |
| Stock Based Compensation | 93.0M | 142M | 226M | 305M | 429M | 450.5M | |
| Free Cash Flow | 2.0B | 13.3B | 4.6B | (3.8B) | (4.1B) | (3.9B) | |
| Change In Working Capital | 2.6B | 990M | (3.5B) | (139M) | (78M) | (74.1M) | |
| Begin Period Cash Flow | 247.7M | 2.6B | 6.9B | 3.2B | 2.9B | 2.1B | |
| Other Non Cash Items | 62.3M | 372M | 59M | (19M) | 17M | 16.2M | |
| Change Receivables | 7.2M | (1.4B) | (1.8B) | 1.8B | 2.1B | 2.2B | |
| Cash And Cash Equivalents Changes | (422.8M) | 2.4B | 4.2B | (3.6B) | (3.3B) | (3.1B) | |
| Cash Flows Other Operating | 16.7M | 3.6B | 2.3B | (5.8B) | (5.3B) | (5.0B) | |
| Issuance Of Capital Stock | 1.9B | (275K) | 65M | 46M | 66M | 62.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.85) | Earnings Share (8.73) | Revenue Per Share | Quarterly Revenue Growth (0.35) | Return On Assets |
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.